Novexel – Acquired by AstraZeneca in 2010 for more than $500 million. Novexel is an emerging specialty pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance. The ever-increasing resistance to marketed antibiotics has led to a clear need for novel anti-infective agents that are active against multi-drug resistant bacteria.
Location: Metropolitan France
Investors 2
| Date | Name | Website |
| - | Sofinnova ... | sofinnovap... |
| - | NeoMed Man... | neomed.net... |